|The announcement title||Patterns of Treatment and Outcome Evaluation in Metastatic Renal Cell Carcinoma Patients in Japan (POEM-RCC Study): The 1st Interim Analysis.|
|Academic Society name||The 110th Annual Meeting of the Japanese Urological Association|
|Conference Type||Domestic Society|
|Announcement form||Poster presentation|
|Presentation Type||General Lecture|
|Society abstract||PP68-01 2023|
Several immune-oncology (IO) agents and/or tyrosine kinase inhibitors (TKIs) have been approved for treatment of metastatic renal cell carcinoma (mRCC) over the last decade in Japan. However, real-world treatment patterns and sequences including clinical outcomes in mRCC patients receiving these agents have not been well studied.
POEM-RCC is a multi-center observational medical chart review study. Eighty academic and community sites in Japan have been participating in this study, and over 1000 patients with mRCC will be enrolled. The objective of this study is to describe patient demographics, clinical characteristics, real-world treatment patterns, sequence of regimens and real-world clinical outcomes by line of therapy of patients initiated with 1st line (1L) systemic anti-cancer treatment. In this analysis, we report interim data from over 500 patients who initiated 1L treatment between November. 1st 2020 to January. 31st 2022 with a minimum of 6-month follow-up.
Patient characteristics such as Age, Clinical stage, IMDC risk, Histology will be reported. Proportion of each drug class (e.g., IO + IO, IO + TKI), each regimen (e.g., Ipilimumab + Nivolumab, Pembrolizumab + Axitinib) of 1L therapy and some of clinical outcomes for 1L treatment will be descriptively presented.
This is the largest real-world study in 1L mRCC Japanese patients describing patient characteristics, treatment patterns, and clinical outcomes in the IO era. The findings from the study may inform treatment decisions for optimal clinical outcomes for these patients.